MET and lung adenocarcinoma: In a series of lung adenocarcinoma patients metastatic to the spine with mutational data for selected markers (ALK, MET, ROS1, EGFR, and KRAS), the presence of clinically targetable mutations was found to be associated with increased survival [37].